S100A8 and S100A9 in Hematologic Malignancies: From Development to Therapy.

Farnaz Razmkhah, Sena Kim, Sora Lim, Abdul-Jalil Dania, Jaebok Choi

International journal of molecular sciences 2023 Aug 29

filter terms:

S100A8 and S100A9 are multifunctional proteins that can initiate various signaling pathways and modulate cell function both inside and outside immune cells, depending on their receptors, mediators, and molecular environment. They have been reported as dysregulated genes and proteins in a wide range of cancers, including hematologic malignancies, from diagnosis to response to therapy. The role of S100A8 and S100A9 in hematologic malignancies is highlighted due to their ability to work together or as antagonists to modify cell phenotype, including viability, differentiation, chemosensitivity, trafficking, and transcription strategies, which can lead to an oncogenic phase or reduced symptoms. In this review article, we discuss the critical roles of S100A8, S100A9, and calprotectin (heterodimer or heterotetramer forms of S100A8 and S100A9) in forming and promoting the malignant bone marrow microenvironment. We also focus on their potential roles as biomarkers and therapeutic targets in various stages of hematologic malignancies from diagnosis to treatment.

Citation

Farnaz Razmkhah, Sena Kim, Sora Lim, Abdul-Jalil Dania, Jaebok Choi. S100A8 and S100A9 in Hematologic Malignancies: From Development to Therapy. International journal of molecular sciences. 2023 Aug 29;24(17)